株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の分子診断市場

Molecular Diagnostics

発行 Global Industry Analysts, Inc. 商品コード 138654
出版日 ページ情報 英文 570 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.58円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界の分子診断市場 Molecular Diagnostics
出版日: 2018年04月01日 ページ情報: 英文 570 Pages
概要

当レポートでは、世界の分子診断市場について調査し、市場の動向と地域別動向、2015〜2022年の予測、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 見通し
    • 世界の体外診断薬 (IVD) 市場は着実に成長
    • 分子診断:IVD市場において急速に拡大するセグメント
    • PCR技術が分子診断市場をリード
    • 現在および将来分析
    • 米国および欧州:市場リーダー
    • 途上国が成長見通し
    • 主な市場促進因子
    • 市場動向
    • 技術動向
    • 分子診断の進歩
    • 主な問題と課題
    • 市場見通し
  • 成長促進因子と市場動向
    • 高齢化が分子診断市場を牽引
    • 世界的高齢人口統計:機会指標
    • 技術革新
    • 個別化医療における分子診断の八鍬w理
    • コンパニオン診断の動向 他
  • 分子診断の応用分野
    • 感染症
    • 子宮頸癌
    • HPV検査
    • 血液スクリーニング
    • 遺伝子疾患検査
  • 分子診断市場における競合動向
    • 競合環境概要
    • 注目企業
    • 主要企業のその技術
  • 製品および技術概要
  • 製品認可/導入
  • 近年の業界活動
  • 主要企業
    • Abbott Laboratories
    • Abbott Molecular, Inc
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Cepheid
    • F. Hoffmann-La Roche Ltd.
    • GE Healthcare
    • Grifols International, S.A.
    • Hologic, Inc.
    • QIAGEN N.V.
    • Quest Diagnostics, Inc.
    • Siemens Healthcare GmBH
    • Tecan Group Ltd.
    • The ELITechGroup SAS
    • Thermo Fisher Scientific
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
目次
Product Code: MCP-1226

This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousand by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 137 companies including many key and niche players such as -

Abbott Laboratories
Becton, Dickinson and Company
bioMerieux SA
Cepheid
F. Hoffmann-La Roche Ltd.
Grifols International, S.A.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

  • Global In-Vitro Diagnostics (IVD) Market on a Steady Growth Path
    • Table 1: Global In-Vitro Diagnostics Market by Segment (2017): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)
    • Table 2: Global In-Vitro Diagnostics Market by Geographic Region (2017): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart)
  • Molecular Diagnostics - A Rapidly Expanding Segment of the IVD Market
  • PCR Technology Leads the MDx Market
  • Current and Future Analysis
  • Leading Players
  • US and Europe - Leaders in Molecular Diagnostics Adoption
  • Developing Countries Excel in Growth Prospects
  • Major Growth Drivers
  • Key Market Trends in a Nutshell
  • Major Technology Trends
  • Oncology Molecular Diagnostics to Witness Rapid Growth...
  • Reagents and Kits Dominate the Molecular Diagnostics Market
  • Based on Test Location
  • Product Innovations Rife in POC Molecular Diagnostics Market
  • Advancements in Molecular Diagnostics - A Boon for the Industry
  • Major Challenges
  • Market Outlook

2. GROWTH DRIVERS AND MARKET TRENDS

  • Aging Population Drives Molecular Diagnostics Market
  • Global Aging Population Statistics - Opportunity Indicators
    • Table 3: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 4: Global Population Statistics for the 60+ Age Group by Region: 2017 (includes corresponding Graph/Chart)
    • Table 5: Global Population Statistics for the 65+ Age Group by Select Countries: 2016 (includes corresponding Graph/Chart)
    • Table 6: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)
  • Technological Innovations Set to Drive the Market
  • The Role of Molecular Diagnostics in Personalized Medicine
  • Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area
    • Table 7: Leading Personalized Medicines Worldwide (2015-2017): Annual Sales of Select Leading Medicines in US$ Million (includes corresponding Graph/Chart)
  • Companion Diagnostics Drive Personalized Medicine
  • List of FDA Approved Complementary and Companion Diagnostic Assays
  • Biomarkers as Companion Diagnostics
  • Rise in Healthcare Spending in Developing Nations Bode Well for Market Growth
    • Table 8: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)
    • Table 9: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2016) (includes corresponding Graph/Chart)
  • Proteomics Technologies: Growing in Significance
  • New Developments in Proteomics Technologies
  • New Applications Hold Promising Potential
  • Molecular Diagnostics for Lymphoid Malignancies
  • Next-Generation Sequencing (NGS) Technologies Keep Up the Momentum
  • Select NGS Platforms Available in the Market
  • Rising Emphasis on Lab Automation to Augur Well for Market Growth
  • List of Fully Automated and Rapid Molecular Diagnostics
  • Molecular Diagnostics and Intellectual Property
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Limited Reimbursements by Third Party Payers - A Stumbling Block

3. APPLICATION AREAS OF MOLECULAR DIAGNOSTICS

  • Infectious Diseases
  • Bright Prospects Ahead for Molecular Diagnostics for Testing Infectious Diseases
  • Leading Players
  • Key Trends
    • Increasing Incidence of Infectious Diseases Fuels Adoption
    • Rising Incidence of Hospital Acquired Infections Propels Market Growth
    • Table 10: Comparison of Different Parameters for Select C. diff MDx Tests
    • Rising HIV Prevalence Provides Ample Growth Opportunities
    • Table 11: HIV Prevalence and Incidence Statistics by Region: 2016 (includes corresponding Graph/Chart)
    • Table 12: HIV Prevalence among the Global Adult Population: 2011-2016
    • Table 13: Regional Data about HIV and AIDS (2016)
    • Infectious Disease Testing - A Major Driver of Molecular Diagnostics Market
      • Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases
    • Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
    • Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
    • HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market
      • List of Select HPV Molecular Diagnostic Tests by Company and Technique
      • Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing
      • Major Risk Factors to HPV/Cervical Cancer
    • Table 14: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart)
    • Table 15: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart)
    • Table 16: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in '000s) (includes corresponding Graph/Chart)
      • HPV Testing for Primary Screening Indication Bodes Well for the Market's Growth
      • Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics
      • List of Select Commercially-Available TB Diagnostics
      • An Overview of Select TB Diagnostics
    • Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential...
    • PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
  • Blood Screening
  • Molecular based Tests Ingrain Roots in Blood Donor Screening Segment
  • Cancer Screening & Diagnosis
  • Overview
  • Molecular Tests Lead the Way for Cancer IVD Market Growth
  • Molecular Markers to Enhance Thyroid Cancer Diagnosis
  • Oncology-Based Molecular Diagnostics: The Propitious Segment
    • List of US-FDA Approved Biomarkers for Cancer
    • Table 17: Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)
    • Table 18: Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)
  • Growing Popularity of Chemo-Sensitivity Testing of CTCs
  • Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
  • Other Testing Applications
  • Genetic Disease Testing Applications
    • Overview
    • Pharmacogenomics - Prognosis Based on Genomics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
    • Prospects for Genetic Diagnostics and Testing Grow Brighter
      • List of Select FDA-Cleared Genetic Tests by Disease
    • Genetic Testing - An Indispensible Tool for Cystic Fibrosis
    • Table 19: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
    • Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions
    • Non-Invasive Prenatal Diagnostics - The Way Ahead
    • Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance
    • PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents

4. COMPETITION IN THE MOLECULAR DIAGNOSTICS MARKET

  • An Overview of Competitive Landscape in Molecular Diagnostics
    • Table 20: Global Molecular Diagnostics Market by Leading Player (2017): Percentage Share Breakdown by Value Sales for Roche, Qiagen, Abbott, GenProbe, Siemens, and Others (includes corresponding Graph/Chart)
  • Other Noteworthy Companies
  • Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market
  • Qiagen: The Leading Player in the Global HPV MDx Market
  • Comparative Analysis of Select HPV MDx Tests
  • Competitive Dynamics in the C. difficile Testing Market
    • Table 21: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2017): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian, and Others (includes corresponding Graph/Chart)
  • List of Select Molecular C. difficile Test Products
  • Competition in the Blood Screening MDx Market
    • Table 22: Global Blood Screening MDx Market by Leading Players (2017): Percentage Market Share Breakdown of Value Sales for Grifols, Roche, and Others (includes corresponding Graph/Chart)
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
  • Competitive Landscape in the Global RT-PCR Market
    • Table 23: Leading Players in Global RT-PCR Instruments Market (2017): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Thermo Fischer, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)
    • Select Real-Time PCR Products by Company
  • Competition Heats Up in dPCR Market
    • Table 24: Leading dPCR Systems at a Glance
  • Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market
  • Consolidation Activity Continues to Strengthen Driven by New Entrants
  • Major M&A Transactions in Molecular Diagnostics: 2011-2018

5. PRODUCT & TECHNOLOGY OVERVIEW

  • Molecular Diagnostics - Definition & Scope
  • Molecular Diagnostics - Impact on Healthcare
  • Utility of Molecular Diagnostic Tests
  • Background of Molecular Diagnostics
  • Types of Molecular Diagnostics
  • Conventional Diagnostics Vs. Molecular Diagnostics
  • Unabated Developments in Molecular Diagnostics Technology
  • Signal Amplification Technologies
    • PCR - New Developments
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
  • Applications of Quantitative Real-Time PCR Analysis
    • Digital PCR
    • Non-PCR Methods
    • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
  • RNA Diagnostics
  • Complementary Molecular Diagnostic Technologies
    • Fluorescent In-Situ Hybridization (FISH)
    • DNA Biochips/Microarrays
    • Biosensors
    • Proteomic Technologies for Molecular Diagnostics
    • Nanotechnology for Molecular Diagnostics
  • Technologies on the Anvil
    • Haplotype Analysis - A Distant Possibility
    • Chronic Multi-Gene Defects Now Diagnosable
  • Whole Genome Sequencing - A Boon or a Bane to Genetic Testing?

6. PRODUCT APPROVALS/INTRODUCTIONS

  • Mobidiag Unveils Novodiag Solution
  • QIAGEN Unveils QFT-Plus
  • Interpace Diagnostics Launches Lung Cancer Test
  • Selfdiagnostics Introduces STD Multitest
  • Multiplicom Releases Extended CE-IVD Certification for all BRCA Testing Needs
  • Admera Health Introduces OncoGxSelect(tm) at the AMP 2016 Annual Meeting
  • Interpace Diagnostics Launches Two New Thyroid Services
  • Abbott Completes the Launch of Alinity(tm)
  • Bio-Rad Introduces Amplichek I Quality Control
  • Qiagen Introduces New Diagnostic Test for Cervical Cancer
  • GE Showcases Discovery MI and Discovery NM/CT 670 CZT
  • Quest Launches New Tests for Determining Hereditary Cancer
  • Predictive Launches Test for Spine Deformities
  • LabCorp(r) Introduces Epi proColon(r)
  • Agena Rolls Out MassARRAY(r) Dx
  • Rosetta Introduces Three New Diagnostic Offerings

7. RECENT INDUSTRY ACTIVITY

  • Randox Partner with Bosch to Introduce Vivalytic
  • Eurofins Acquires NMDL-LCPL
  • QIAGEN N.V Acquires STAT-Dx
  • Siemens Healthineers Acquires Fast Track Diagnostics
  • General Atomics Buys Assets of Xagenic, Inc
  • QIAGEN Establish Custom Solutions Business
  • Abbott Acquires Alere, Inc
  • Biocartis Extends Partnership with ETPL
  • Agilent Technologies Signs Agreement with Agendia on Molecular Cancer Diagnostics
  • AID Partners Capital Takes over Israeli Medical Diagnostic
  • Agilent Technologies Acquires Multiplicom N.V
  • ELITechGroup agrees with Abbott's Molecular Business, for Distributing Molecular Diagnostic Reagents
  • Miragen Therapeutics and Signal Genetics Agrees to Merge
  • New England Biolabs(r) Agrees with AmpTec GmbH for Supplying key mRNA Synthesis Reagents
  • Seegene and Hamilton Signs Agreement for Developing Molecular Diagnostics System
  • Transgenomic and Precipio Diagnostics Agrees to Merge
  • Sedia Biosciences and Floragenex Completes Merger
  • Interpace Diagnostics Group Completes the Launch of PanDNA(r)
  • WuXi AppTec's Laboratory Testing Division Enters into a Distributor Agreement with AutoGenomics
  • Danaher Corporation Enters into Merger Agreement with Cepheid
  • Interpace Diagnostics Group, Inc. Extends Agreement with LabCorpLH
  • Agilent Technologies Agrees with Burning Rock to Develop Cancer Diagnostics in China
  • Bio-Techne to Acquire Advanced Cell Diagnostics
  • Myriad Acquires Sividon Diagnostics
  • Siemens Acquires Neo New Oncology
  • Luminex to Acquire Nanosphere
  • DiaSorin Completes Acquisition of Focus Diagnostics
  • Avant Acquires Amarantus Diagnostics
  • HTG to Collaborate With Bristol-Myers Squibb
  • Miroculus to Acquire Kapplex
  • Cepheid's Xpert(r) MRSA NxG Gets European Approval
  • SpeeDx Collaborates with Goffin Molecular
  • FDA Approves BD's Totalys(tm)
  • BioFire Diagnostics' FilmArray(r) Obtains CE Mark Approval
  • Thermo Fisher Acquires Affymetrix
  • Qiagen Collaborates with Mirati
  • BioGenex to Commence Operations from India Center
  • Illumina Collaborates with investors to Launch GRAIL

8. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • Abbott Molecular (USA)
  • Becton, Dickinson and Company (USA)
  • bioMerieux SA (France)
  • Cepheid (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Grifols International, S.A. (Spain)
  • Hologic, Inc. (USA)
  • QIAGEN N.V. (The Netherlands)
  • QuestDiagnostics, Inc. (USA)
  • Siemens Healthcare GmBH (Germany)
  • Tecan Group Ltd. (Switzerland)
  • The ELITechGroup (France)
  • Thermo Fisher Scientific (USA)

9. GLOBAL MARKET PERSPECTIVE

    • Table 25: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 27: World 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
  • Molecular Diagnostics Market by Application
    • Table 28: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 29: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 30: World 14-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
    • Table 31: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 32: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 33: World 14-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
    • Table 34: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 35: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 36: World 14-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
    • Table 37: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 38: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 39: World 14-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US Molecular Diagnostics Market Maintain its Growth Momentum
    • Table 40: Diagnoses of HIV Infection in the US (2015 & 2016) (includes corresponding Graph/Chart)
    • Table 41: AIDS Stage 3 Diagnoses in the US (2011-2016) (includes corresponding Graph/Chart)
    • Table 42: New Cancer Cases in the US by State (2017E) (includes corresponding Graph/Chart)
    • Table 43: Number of Deaths Related to Major Types of Cancer in US by State: 2017E (includes corresponding Graph/Chart)
    • Competitive Landscape
    • qPCR and dPCR Instrumentation in the US: An Overview
    • Ageing Demographics: Major Driving Factor
    • Table 44: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 45: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Increasing Incidence of Chronic Diseases Drives Focus onto Molecular Diagnostics
    • US Personalized Medicine Market to Witness Significant Growth
    • Companion Diagnostics Market in the US
      • List of FDA Approved Complementary and Companion Diagnostic Assays
    • Burgeoning Potential for Genetic Testing
      • Direct-to-Consumer Testing - A Growing Market
    • Epidemic Proportion of Cancer in the US - Key Driver for Cancer Genetic Testing
    • Table 46: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)
    • Table 47: Cancer Related Deaths by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
      • List of FDA-Cleared CF MDx Tests
    • Molecular Diagnostics Tests Gaining Share in STD Testing Domain
    • HPV Testing Market - A Review
    • Table 48: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)
    • Table 49: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart)
      • Competitive Landscape
      • List of FDA Approved HPV MDx Tests
    • Regulatory Environment
      • FDA Regulations
      • Clinical Laboratory Improvement Amendments (CLIA)
    • Table 50: Number of CLIA-Certified Laboratories in the US by Certificate Type: (January 2018) (includes corresponding Graph/Chart)
    • Table 51: CLIA-Certified Laboratories in the US (2018): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart)
      • Genetic Testing
      • FDA to Implement Strict Measures for Cervical Cancer Screening Tests
      • Limited Reimbursements - A Major Hindrance
      • New MoPath Codes for Reimbursement for Molecular Diagnostics Tests
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 52: The US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 53: The US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 54: The US 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Cancer Incidence in Canada: Opportunity Indicator
    • Table 55: New Cancer Cases in Canada (2017E): Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)
    • Table 56: New Cancer Cases in Canada by Province: 2017E (includes corresponding Graph/Chart)
    • Table 57: New Cancer Cases in Canada by Age Group: 2017E (includes corresponding Graph/Chart)
    • Table 58: Cancer Related Deaths in Canada (2017E): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 59: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 60: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 61: Canadian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Demographics Drive Market Growth
    • Table 62: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Table 63: Japanese Population by Age Group (2017E): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 65 Years and Above (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 64: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 65: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 66: Japanese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 67: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
    • Regulatory Scenario in Europe for Companion Diagnostics
      • Companion Diagnostics: Select European Players with Strong Biomarker Pipeline
    • The Need for Improving Reimbursement Policies
    • Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics
    • Table 68: EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)
    • PCR Reagents in Europe: An Overview
    • Automated Systems Gain Preeminence
    • Oncology-based Molecular Diagnostics Holds Immense Potential
    • Table 69: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)
    • Europe Heading towards Massive Improvements in Personalized Medicine
    • Personalized Medicine Big on EU Agenda - A Peek into EC Investments in This Space
    • HPV Testing in Europe: An Overview
    • Table 70: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)
    • Table 71: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 72: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 73: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)
      • List of Select CE-Marked HPV Molecular Diagnostic Tests
    • Cervical Cancer Screening in Europe - A Review
    • Table 74: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart)
    • Table 75: Cervical Cancer Incidence and Mortality in European Countries (2012)
    • Table 76: Prevalence of Cervical Cancer in European Countries (2012)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 77: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 78: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 79: European 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
    • Table 80: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 81: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 82: European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
    • Select Key Players
  • B. Market Analytics
    • Table 83: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 84: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 85: French 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches
    • Strategic Corporate Development
    • Siemens Healthcare GmBH (Germany) - A Key Player
  • B. Market Analytics
    • Table 86: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 87: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 88: German 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 89: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 90: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 91: Italian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 92: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 93: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 94: The UK 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current and Future Analysis
    • Spain - Poised to become a Reckoning Force in Personalized Medicines
    • Grifols International, S.A. (Spain) - A Key Player
  • B. Market Analytics
    • Table 95: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 96: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 97: Spanish 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 98: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 99: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 100: Russian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch/Approval
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 102: Rest of Europe Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 103: Rest of Europe 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • A Prelude into Asia-Pacific Market:
    • Healthcare Spending in Asia-Pacific: On the Rise
    • In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities
    • Molecular Diagnostics Testing Opens New World of Possibilities
    • Recent Advancements in Molecular Diagnostics Market: A Quick Review
      • Novel Genetic Testing Methods
      • Development of Personalized Healthcare Approaches
      • Molecular Painting for Genetic Diagnosis of Diseases
      • New Technique to Detect H1N1 Virus
  • B. Market Analytics
    • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 105: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 106: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
    • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 108: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 109: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • In-Vitro Diagnostics Market on the Growth Curve
    • HPV Testing in China: An Overview
    • Government Support Drives Personalized Medicine Market in China
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 110: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 111: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 112: Chinese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • A Focus on the Indian Molecular Diagnostics Market
      • Molecular Diagnostic Market in India to Witness Significant Growth
      • Growth Drivers in a Nut Shell
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • Indian Scientific Research towards Functional Genomics and Proteomics
      • Automation - The Emerging Trend in IVD Industry
      • HPV Testing Market: An Overview
    • Table 113: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 114: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 115: Rest of Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 116: Rest of Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
    • Brazilian IVD Market on the Rise
  • B. Market Analytics
    • Table 117: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 118: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 119: Latin American 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 120: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 121: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 122: Rest of World 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)
Back to Top